Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
BACKGROUND
FRAME was a prospective observational study that captured real-world data on patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapies as first-line treatment (FLT) across Europe. As previously reported, most patients observed in the study had initiated FLT with either pemetrexed, gemcitabine, vinorelbine or taxanes in combination with a platinum. Baseline patient and disease characteristics including age, performance status, and histology varied (all p<0.01) across cohorts.


METHODS
Consenting adult patients initiating FLT for advanced or metastatic NSCLC with platinum-based chemotherapy, with or without a targeted agent, entered the study between April 2009 and February 2011. The choice of FLT was left to physicians' discretion per routine clinical practice. The primary objective was to evaluate overall survival (OS) across platinum-based doublet chemotherapy cohorts and key secondary objectives included the evaluation of OS in patients with different histological subtypes of NSCLC. Survival outcomes were assessed using Kaplan-Meier analysis, and unadjusted estimates are presented.


RESULTS
Median OS in months was 10.3 across cohorts (n=1524), 10.7 for pemetrexed (n=569), 10.0 for gemcitabine (n=360), 9.1 for taxanes (n=295), and 10.7 for vinorelbine (n=300). For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine.


CONCLUSIONS
FRAME describes real-world treatment patterns and survival for patients initiating FLT for advanced or metastatic NSCLC between 2009 and 2011 across Europe.
Unité d'Oncologie Thoracique-Pneumologie, CHU de Grenoble, INSERM U823 Grenoble, France. Electronic address: DMoro-Sibilot@chu-grenoble.fr.
Denis
D
Moro-Sibilot
Vrije Universiteit Medical Centre, Amsterdam, The Netherlands.
Egbert
E
Smit
Hospital Universitario La Paz, Madrid, Spain.
Javier
J
de Castro Carpeño
Medical University of Gdańsk, Gdynia, Poland.
Krzysztof
K
Lesniewski-Kmak
Amphia Hospital Breda, Rotterdam, The Netherlands; Erasmus MC, Rotterdam, The Netherlands.
Joachim
J
Aerts
Hospital Costa del Sol, Marbella, Spain.
Rosa
R
Villatoro
Eli Lilly and Company, Houten, The Netherlands.
Kees
K
Kraaij
Eli Lilly and Company, Neuilly-sur-Seine, France.
Karim
K
Nacerddine
Eli Lilly GmbH, Vienna, Austria.
Yulia
Y
Dyachkova
Eli Lilly and Company, Indianapolis, IN, USA.
Karen T
KT
Smith
Oy Eli Lilly, Ab, Finland.
Kaisa
K
Taipale
Eli Lilly and Company, Indianapolis, IN, USA.
Allicia C
AC
Girvan
Eli Lilly and Company, Houten, The Netherlands.
Carla
C
Visseren-Grul
Pathologisches Institut, Universitätsklinikum, Heidelberg, Germany.
Philipp A
PA
Schnabel
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005060:Europe; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000068437:Pemetrexed / Q000008:administration & dosage; D011446:Prospective Studies; D043823:Taxoids / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D000093542:Gemcitabine
D009944:Organoplatinum Compounds; D043823:Taxoids; D000068437:Pemetrexed; D003841:Deoxycytidine; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine; D000093542:Gemcitabine
Health resources; Non-small cell lung cancer (NSCLC); Observational study; Survival